On Tuesday, Biogen and Ionis announced that their Alzheimer's treatment aimed at targeting tau proteins resulted in a 26% reduction in cognitive decline within an 18-month period. However, despite this positive outcome, Biogen experienced a decline in its stock value as the Alzheimer's study raised uncertainties rather than providing clear answers.